Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01858948 · ClinicalTrials.gov registry record · Phase 3
SGA-induced Metabolic Syndrome in Bipolar Youth
A Phase 3 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT01858948 is a Phase 3 study that has completed, run by University of Cincinnati. The registered enrollment target is 19 participants.
The verdict
NCT01858948, a Phase 3 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
The investigators tested the hypothesis that long-chain omega-3 (LCn-3) fatty acid supplementation will attenuate the adverse cardiometabolic effects of second-generation antipsychotics exposure in first-episode adolescent manic patients.
Interventions
- DRUG Placebo
- DRUG Quetiapine fumarate
- DRUG Omega
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-07 |
| Est. Completion | 2018-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01858948
The ClinicalTrials.gov registry entry for NCT01858948 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01858948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01858948 about?
NCT01858948 is a clinical study titled "SGA-induced Metabolic Syndrome in Bipolar Youth". The investigators tested the hypothesis that long-chain omega-3 (LCn-3) fatty acid supplementation will attenuate the adverse cardiometabolic effects of second-generation antipsychotics exposure in first-episode adolescent manic patients.
What is the current status of trial NCT01858948?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2013-07. Estimated completion is 2018-04.
What interventions are being tested in trial NCT01858948?
The interventions under investigation include: Placebo (DRUG), Quetiapine fumarate (DRUG), Omega (DRUG).
Who is sponsoring clinical trial NCT01858948?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.